APLS logo

Apellis Pharmaceuticals (APLS) EBITDA

Annual EBITDA

-$495.21 M
+$122.18 M+19.79%

December 31, 2023

Summary

Performance

1-Year Change

+19.79%

3-Year Change

-58.6%

5-Year Change

-296.2%

15-Year Change

-878.07%

APLS EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

1.75%
APLS annual EBITDA is higher than 1.75% of companies in Healthcare sector

High & Low

All-time High

-$4.02 M

3-Year Low

-$731.27 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
APLS previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Feb 27, 2025
APLS next annual earnings announcement is scheduled for Feb 27, 2025

OtherAPLSprofitabilitymetrics:

Annual Revenue

$396.59 M
APLS annual revenue is $396.59 million

Annual Net Income

-$528.63 M
APLS annual net profit is -$528.63 million

Annual EBIT

-$496.92 M
APLS annual earnings before interest & taxes is -$496.92 million

Annual EPS

-$4.45
APLS annual earnings per share is -$4.45

Quarterly EBITDA

-$43.70 M
-$15.91 M-57.25%

September 30, 2024

Summary

Performance

3-Month Change

-57.25%

1-Year Change

+44.87%

3-Year Change

+69.69%

5-Year Change

+69.69%

APLS Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

9.9%
APLS quarterly EBITDA is higher than 9.9% of companies in Healthcare sector

High & Low

All-time High

$90.00 M
APLS quarterly EBITDA is currently -148.56% below its historical high of $90.00 million

3-Year Low

-$182.56 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
APLS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 27, 2025
APLS next earnings announcement is scheduled for Feb 27, 2025

OtherAPLSprofitabilitymetrics:

Quarterly Revenue

$196.83 M
APLS quarterly revenue is $196.83 million

Quarterly Net Income

-$57.45 M
APLS quarterly net profit is -$57.45 million

Quarterly EBIT

-$44.32 M
APLS quarterly earnings before interest & taxes is -$44.32 million

Quarterly EPS

-$0.46
APLS quarterly earnings per share is -$0.46

TTM EBITDA

-$209.71 M
+$88.59 M+29.70%

September 30, 2024

Summary

Performance

3-Month Change

+29.7%

1-Year Change

+57.65%

3-Year Change

+71.32%

5-Year Change

+71.32%

APLS TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

7.38%
APLS TTM EBITDA is higher than 7.38% of companies in Healthcare sector

High & Low

All-time High

-$2.67 M

3-Year Low

-$731.27 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
APLS previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Feb 27, 2025
APLS next earnings announcement is scheduled for Feb 27, 2025

OtherAPLSprofitabilitymetrics:

TTM Revenue

$715.22 M
APLS TTM revenue is $715.22 million

TTM Net Income

-$250.10 M
APLS TTM net profit is -$250.10 million

TTM EBIT

-$211.54 M
APLS TTM earnings before interest & taxes is -$211.54 million

TTM EPS

-$2.03
APLS TTM earnings per share is -$2.03

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

Annual EBITDA

-$495.21 M
APLS annual EBITDA is -$495.21 million

Annual Net Income

-$528.63 M
APLS annual net profit is -$528.63 million

Annual Interest Expense

$29.58 M
APLS annual interest expense is $29.58 million

Annual Income Tax

$2.13 M
APLS annual income tax is $2.13 million

Annual D&A

$1.70 M
APLS annual depreciation & amortization is $1.70 million

APLS EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+19.8%+44.9%+57.6%
3 y3 years-58.6%+69.7%+71.3%
5 y5 years-296.2%+69.7%+71.3%

APLS EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+32.3%-57.3%+76.1%at high+71.3%
5 y5-year-65.7%+32.3%-148.6%+79.7%at high+71.3%
alltimeall time<-9999.0%+32.3%-148.6%+79.7%-7763.1%+71.3%

Apellis Pharmaceuticals EBITDA History

DateAnnualQuarterlyTTM
Sep 2024
-
-$43.70 M(+57.3%)
-$209.71 M(-29.7%)
Jun 2024
-
-$27.79 M(-52.9%)
-$298.30 M(-22.4%)
Mar 2024
-
-$58.96 M(-25.6%)
-$384.60 M(-22.3%)
Dec 2023
-$495.21 M(-19.8%)
-$79.26 M(-40.1%)
-$495.21 M(-13.9%)
Sep 2023
-
-$132.29 M(+15.9%)
-$575.25 M(-8.0%)
Jun 2023
-
-$114.09 M(-32.7%)
-$625.52 M(-5.0%)
Mar 2023
-
-$169.57 M(+6.4%)
-$658.13 M(+6.6%)
Dec 2022
-$617.39 M(-15.6%)
-$159.30 M(-12.7%)
-$617.39 M(+2.5%)
Sep 2022
-
-$182.56 M(+24.4%)
-$602.28 M(-1.7%)
Jun 2022
-
-$146.70 M(+13.9%)
-$612.73 M(-10.0%)
Mar 2022
-
-$128.83 M(-10.7%)
-$681.01 M(-6.9%)
Dec 2021
-$731.27 M(+134.2%)
-$144.19 M(-25.3%)
-$731.27 M(+47.1%)
Sep 2021
-
-$193.01 M(-10.2%)
-$497.08 M(+15.6%)
Jun 2021
-
-$214.98 M(+20.0%)
-$429.95 M(+31.7%)
Mar 2021
-
-$179.09 M(-299.0%)
-$326.56 M(+4.6%)
Dec 2020
-$312.23 M(+4.5%)
$90.00 M(-171.5%)
-$312.23 M(-38.9%)
Sep 2020
-
-$125.89 M(+12.8%)
-$511.30 M(+12.5%)
Jun 2020
-
-$111.59 M(-32.3%)
-$454.50 M(+9.9%)
Mar 2020
-
-$164.76 M(+51.1%)
-$413.72 M(+38.4%)
DateAnnualQuarterlyTTM
Dec 2019
-$298.83 M(+139.1%)
-$109.07 M(+57.9%)
-$298.83 M(+32.6%)
Sep 2019
-
-$69.08 M(-2.4%)
-$225.40 M(+17.8%)
Jun 2019
-
-$70.81 M(+42.0%)
-$191.29 M(+24.9%)
Mar 2019
-
-$49.87 M(+39.9%)
-$153.21 M(+23.1%)
Dec 2018
-$124.99 M(+146.9%)
-$35.64 M(+1.9%)
-$124.41 M(+16.7%)
Sep 2018
-
-$34.97 M(+6.8%)
-$106.63 M(+28.1%)
Jun 2018
-
-$32.73 M(+55.3%)
-$83.25 M(+32.9%)
Mar 2018
-
-$21.07 M(+18.0%)
-$62.65 M(+23.7%)
Dec 2017
-$50.63 M(+86.7%)
-$17.86 M(+54.1%)
-$50.63 M(+28.8%)
Sep 2017
-
-$11.59 M(-4.5%)
-$39.30 M(+12.5%)
Jun 2017
-
-$12.13 M(+34.0%)
-$34.94 M(+53.2%)
Mar 2017
-
-$9.05 M(+38.8%)
-$22.81 M(+65.8%)
Dec 2016
-$27.12 M(+35.0%)
-$6.52 M(-9.9%)
-$13.76 M(-3.1%)
Sep 2016
-
-$7.23 M(+3.9%)
-$14.20 M(+17.1%)
Dec 2015
-$20.09 M(+78.0%)
-$6.96 M(+35.0%)
-$12.12 M(+50.2%)
Sep 2015
-
-$5.16 M(+77.0%)
-$8.07 M(+44.6%)
Dec 2014
-$11.29 M(+180.6%)
-$2.91 M(+9.3%)
-$5.58 M(+109.3%)
Sep 2014
-
-$2.67 M
-$2.67 M
Dec 2013
-$4.02 M
-
-

FAQ

  • What is Apellis Pharmaceuticals annual EBITDA?
  • What is the all time high annual EBITDA for Apellis Pharmaceuticals?
  • What is Apellis Pharmaceuticals annual EBITDA year-on-year change?
  • What is Apellis Pharmaceuticals quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Apellis Pharmaceuticals?
  • What is Apellis Pharmaceuticals quarterly EBITDA year-on-year change?
  • What is Apellis Pharmaceuticals TTM EBITDA?
  • What is the all time high TTM EBITDA for Apellis Pharmaceuticals?
  • What is Apellis Pharmaceuticals TTM EBITDA year-on-year change?

What is Apellis Pharmaceuticals annual EBITDA?

The current annual EBITDA of APLS is -$495.21 M

What is the all time high annual EBITDA for Apellis Pharmaceuticals?

Apellis Pharmaceuticals all-time high annual EBITDA is -$4.02 M

What is Apellis Pharmaceuticals annual EBITDA year-on-year change?

Over the past year, APLS annual EBITDA has changed by +$122.18 M (+19.79%)

What is Apellis Pharmaceuticals quarterly EBITDA?

The current quarterly EBITDA of APLS is -$43.70 M

What is the all time high quarterly EBITDA for Apellis Pharmaceuticals?

Apellis Pharmaceuticals all-time high quarterly EBITDA is $90.00 M

What is Apellis Pharmaceuticals quarterly EBITDA year-on-year change?

Over the past year, APLS quarterly EBITDA has changed by +$35.56 M (+44.87%)

What is Apellis Pharmaceuticals TTM EBITDA?

The current TTM EBITDA of APLS is -$209.71 M

What is the all time high TTM EBITDA for Apellis Pharmaceuticals?

Apellis Pharmaceuticals all-time high TTM EBITDA is -$2.67 M

What is Apellis Pharmaceuticals TTM EBITDA year-on-year change?

Over the past year, APLS TTM EBITDA has changed by +$285.50 M (+57.65%)